Yakup Ergün· @dr_yakupergun · X·· 2 days agoScore70
Body
#ESMO26 | DESTINY-Breast11
MRI response does not reliably predict pCR. An important limitation for response-guided personalization of neoadjuvant treatment.
1220 views · 14 likes · 5 reposts · 0 replies
Conference abstracts
543ROmatched by Rapid oral: Breast cancer, early stage
DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com